Business Wire

NTT

15.5.2020 08:02:11 CEST | Business Wire | Press release

Share
NTT: Conclusion of a Cooperation Agreement with ITER

NTT Corporation (NTT, President & CEO: Jun Sawada) concluded a Cooperation Agreement on the ITER Project with the ITER International Fusion Energy Organization (ITER Organization).
By supporting the ITER Project, which has the objective of building the world’s first experimental hydrogen fusion reactor, NTT will accelerate “Development of innovative environment and energy technologies”, and contribute to the reduction of the environmental impact of customers, companies and society.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200514005951/en/

1. Background
The ITER Project is an extraordinarily large international project that has the objective of building the world’s first experimental hydrogen fusion reactor (ITER) to prove the scientific and technical feasibility of the fusion energy for peaceful purposes. The ITER Organization, an international organization with seven members – Japan, the European Union, Russia, the United States, South Korea, China, and India – is engaged in the ITER Project.

NTT is aiming at “Zero Environmental Impact” by supporting customers, enterprises, and society in reducing their impact on the environment through our R&D aimed at creating innovations that break through conventional limitations and by pursuing business activities designed to decrease deleterious effects on the environment. For example, NTT is preparing to establish the Space Environment and Energy Laboratories, which will undertake research with the goal of creating innovative energy and environmental technologies.
NTT assumes the use of photonic technologies developed for IOWN* concept, and will work to extend the current ICT technologies, which would benefit the ITER Project.
*IOWN (Innovative Optical and Wireless Network) is a future communications infrastructure to create a smarter world by using cutting-edge technologies like photonics and computing technologies.
https://www.rd.ntt/e/iown/

2. Scope of Cooperation
Under the strategic intent of this Cooperation Agreement, NTT will collaborate in the following areas.

  • Exploration of innovative future Information and Communication Technology, including ultra-high-speed network, ultra-low latency network connectivity, data storage, computing, and global network infrastructure.
  • Exploration of the concept “IOWN” including All-Photonics Network, Digital Twin Computing, and Cognitive Foundation.

This is the first time that the ITER Organization has signed a Long Term Non-Commercial Cooperation Agreement with a private Japanese company. As a general ICT player capable of providing full-stack, full-lifecycle services on a global scale, the NTT Group will collaborate on information distribution and control platforms in preparation for ITER’s first plasma in 2025 and beyond.
NTT will work out the details and conclude an implementation agreement.

3. Executive statements
“With an aim of achieving zero environmental impact, NTT is conducting R&D to create the innovations needed to achieve this goal, and carrying out its business activities in a manner that reduces its effects on the environment. Safe and permanent fusion energy is one of the most promising technologies in this important endeavor. We believe that NTT’s groundbreaking R&D activities, including IOWN, and our ability to construct global infrastructure can make a valuable contribution to the ITER Organization, a leading research entity in this area. Under this agreement, we will work closely with the ITER Organization to demonstrate the feasibility of fusion power at an industrial scale for the first time in human history.”
-Jun Sawada , President & CEO, NTT

“We, with the seven ITER Members, believe that fusion power can become a clean and safe vital contributor to the global energy mix for our civilization starting in this century for numerous millennium, and the progress of the ITER Project is essential for that path. I am pleased to have global ICT companies like NTT as one of our long-term non-commercial collaboration partners, with the solid capacity to develop advanced global ICT technologies as well as the capability to envision innovative future technologies strategies such as the IOWN concept that fusion will definitively need.”
-Bernard Bigot , Director-General, the ITER Organization

About NTT
NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.
As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press release

Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burdenEnpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standardsELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People

Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 14:00:00 CEST | Press release

Celebrating the ecommerce leaders from Michael Kors and Gymshark shaping the future of fraud prevention and risk management Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are:Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of

The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 14:00:00 CEST | Press release

The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release

Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w

Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release

Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye